Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Uppsala, Sweden, May 6, 2026. Dicot Pharma AB held its Annual General Meeting today in Uppsala where the following decisions were made.
Annual report and results
The meeting adopted the income statements and balance sheets according to the accounting documents presented and decided in accordance with the Board's proposal that the profit for the year be carried forward. No dividend will be paid.
Discharge from liability
The Meeting discharged the members of the Board of Directors and the Managing Director from liability for the management of the company's affairs during the financial year 2024.
Election of the Board of Directors and auditor
It was resolved to reduce the number of Directors from six to five. It was resolved to re-elect Eva Sjökvist Saers, Fredrik Buch, Mikael von Euler, Per-Göran Gillberg and Jan-Eric Österlund as ordinary Dirctors. Eva Sjökvist Saers was re-elected as Chairman of the Board.
The Meeting resolved to re-elect Öhrlings PricewaterhouseCoopers AB as auditor with Lars Kylberg as auditor in charge.
Board and auditor fees
It was resolved that Board fees shall be paid in the amount of SEK 125,000 for ordinary Directors and SEK 250,000 for the Chairman, an increase of SEK 25,000 and SEK 50,000 respectively. It was resolved that the auditor's fee shall be paid on current account.
Resolution on the Nomination Committee
The AGM resolved that Dicot Pharma, prior to the 2026 AGM, shall have a nomination committee that shall submit proposals for, among other things, Directors, Board fees, and auditor. The members of the Nomination Committee are appointed by the Chairman of the Board contacting the three largest shareholders in the company as of September 30, 2026, and asking them to appoint one representative each to constitute the Nomination Committee together with the Chairman of the Board.
Employee stock option program 2025/2030
The AGM resolved to introduce an incentive program for employees and the CEO through a directed issue of warrants to Dicot Pharma (with approval for onward transfer to the participants in the program). The warrant program comprises a total of 5,000,000 warrants.
The above resolutions were passed with the required majority.
For more detailed information on the content of the resolutions, please refer to the full notice of the Annual General Meeting available in Swedish at www.dicotpharma.com.